secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001213900-24-018789
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics amends convertible notes to cap conversion at 19.9% without stockholder approval
--------------------------------------------------------------------------------

- Amendment dated Feb 27, 2024 between Allarity and holder 3i, LP modifies two senior convertible notes from Jan and Feb 2024.
- New provision bars conversion or share issuance if it would exceed 19.9% of outstanding common stock absent stockholder approval.
- All other terms of the Notes remain in full force and effect.
- Company also furnished an updated corporate presentation on its website (no specific material details provided in this filing).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024018789/0001213900-24-018789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024018789/ea0200995-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-018789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer